Is a 3.25 mg dose of mirtazapine appropriate for treating insomnia?

Mirtazapine 3.25mg is NOT an appropriate dose for treating insomnia

The dose of 3.25mg mirtazapine is below the minimum effective dose studied and recommended for insomnia treatment. The FDA-approved starting dose for mirtazapine is 15mg daily for depression 1, and off-label use for insomnia typically employs doses of 7.5-15mg, not 3.25mg.

Evidence-Based Dosing for Insomnia

Guideline Recommendations

The American Academy of Sleep Medicine (AASM) guidelines position mirtazapine as a third-line option for chronic insomnia, to be considered only after:

1. First-line: Benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) or ramelteon
2. Second-line: Alternative BzRAs if initial agent unsuccessful
3. Third-line: Sedating antidepressants like mirtazapine, especially when comorbid depression/anxiety exists 2

Critical caveat: The AASM explicitly states that mirtazapine and other sedating antidepressants are "not FDA approved for insomnia and their efficacy for this indication is not well established" 2. The 2017 AASM guideline notably does not include mirtazapine in their formal recommendations, focusing instead on FDA-approved agents 3.

Research Evidence on Effective Doses

The most recent high-quality evidence demonstrates:

• 7.5-15mg is the studied dose range: A 2025 randomized controlled trial in older adults (MIRAGE study) used 7.5mg mirtazapine and showed significant reduction in Insomnia Severity Index scores (-6.5 points vs -2.9 for placebo, p=0.003) 4. This is the highest quality evidence available.

• 7.5mg appears optimal: Another 2025 RCT (DREAMING study) using 7.5-15mg mirtazapine showed clinically relevant improvement at 6 weeks (mean ISI reduction of -6.0 points vs placebo, p<0.05), with 52% achieving improvement and 56% achieving recovery 5. A 2015 retrospective study found that 7.5mg corresponded to the highest percentage of responders (52.5%) 6.

• 3.25mg has no evidence base: No published studies have evaluated 3.25mg mirtazapine for insomnia. This dose is approximately half the minimum studied dose.

Why This Dose is Problematic

Pharmacological Rationale

Mirtazapine's sedating effects come primarily from:

• H1 histamine receptor antagonism (sedation)
• 5-HT2 serotonin receptor antagonism (sleep architecture improvement)

At very low doses (<7.5mg), there may be insufficient receptor occupancy to produce therapeutic effects. The dose-response relationship shows that lower doses (7.5-15mg) were more effective than higher doses (15-30mg) in treating insomnia 6, but this doesn't extrapolate to sub-therapeutic doses like 3.25mg.

Safety Considerations

Even at appropriate doses, mirtazapine carries risks:

• Daytime somnolence: Reported in 54% of patients in controlled trials 1
• Weight gain: 49% of patients gained ≥7% body weight in pediatric trials 1
• Next-day cognitive impairment: Demonstrated in controlled studies 7
• QT prolongation risk: Particularly with cardiovascular disease or concomitant QT-prolonging drugs 1

The FDA label explicitly states: "The recommended starting dose of mirtazapine tablets is 15 mg once daily" 1. Using 3.25mg represents off-label use at a sub-therapeutic dose with no evidence of efficacy.

Recommended Approach

If considering mirtazapine for insomnia:

1. First ensure appropriate patient selection:

   • Failed first-line agents (BzRAs, ramelteon)
   • Comorbid depression or anxiety present
   • No contraindications (cardiovascular disease, seizure disorder, hepatic impairment)

2. Use evidence-based dosing:

   • Start at 7.5mg nightly (can split a 15mg tablet)
   • May increase to 15mg if inadequate response after 1-2 weeks
   • Maximum studied dose for insomnia: 15mg

3. Monitor for adverse effects:

   • Next-day sedation and cognitive impairment
   • Weight gain and increased appetite
   • Discontinue if adverse effects outweigh benefits

4. Consider superior alternatives:

   • Doxepin 3-6mg: The only antidepressant with AASM recommendation for sleep maintenance insomnia 3
   • FDA-approved hypnotics: Zolpidem, eszopiclone, zaleplon for sleep onset; eszopiclone or suvorexant for sleep maintenance 3

Bottom line: 3.25mg mirtazapine lacks any evidence base and falls below the minimum effective dose. If mirtazapine is appropriate for the patient, use 7.5mg as the starting dose based on the strongest available evidence 5, 4.